Mednet Logo
CommunityHematology

In patients with Philadelphia-negative ALL who are transplant ineligible, is there any data to guide the duration of maintenance POMP therapy?

Does your approach change if the MRD is negative post-blinatumomab?
1 Answer
Mednet Member
Mednet MemberInvited Expert
Medical Oncology · University of Washington
Answered on · Updated on

To my knowledge, there have not been any prospective trials in the modern era that specifically address the issue of the duration of maintenance therapy in adults with ALL.

Most regimens that have been studied provide a timeframe over which maintenance therapy should be administered, and nearly all h...

Join for free or sign in to see the full answer